INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Insys Therapeutics (INSY): Syndros Approval Should Contribute $220M - RBC
July 5, 2016 8:45 AM UTCRBC Capital analyst, Randall Stanicky, noted that this morning, INSYS Therapeutics (NASDAQ: INSY) announced that it has received approval for Syndros (Dronabinol OS), its cannabinoid dronabinol oral solution. The product will be used to treat AIDS-related anorexia and nausea and vomiting in patients receiving... More
Insys Therapeutics' (INSY) Syndros Approved by FDA
July 5, 2016 6:56 AM UTCInsys Therapeutics, Inc. (Nasdaq: INSY) announced that the U.S. Food and Drug Administration (FDA) has approved Insys dronabinol oral solution, Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration.
"We are very pleased... More
